- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01453153
Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer
A Phase 1b/2 Multicenter, International, Randomized, Double Blind, Placebo-Controlled, Study of Gemcitabine Combined With PEGPH20 Compared to Gemcitabine Combined With Placebo in Patients With Stage IV Previously Untreated Pancreatic Cancer
Phase 1B: Open label (all patients receive PEGPH20+gemcitabine), dose escalation, safety and tolerability study to determine the safe dose of PEGPH20 to use in combination with gemcitabine in Stage IV previously untreated pancreatic cancer patients.
Phase 2: Randomized, double blind study to compare the effect of overall survival of gemcitabine plus PEGPH20 vs gemcitabine plus placebo in Stage IV previously untreated pancreatic cancer patients.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PEGPH20 is a PEGylated version of human recombinant PH20 hyaluronidase that, in preclinical studies, has been shown to remove HA from the extracellular matrix surrounding tumor cells by depolymerizing this substrate. 87% of pancreatic ductal adenocarcinomas (PDA) overexpress HA. PDA tumor tissue may be especially sensitive to the HA-degradation properties of PEGPH20 and thus more responsive to the cytotoxic effects of a given dose of gemcitabine. Modifying the extracellular environment to increase the penetration and efficacy of anti-cancer agents represents a novel approach to treating pancreatic cancer and may provide important therapeutic outcomes in patients with Stage IV Previously Untreated Pancreatic Cancer.
This Phase 1B/2 study will assess safety, tolerability, treatment effect, and various PK/PD endpoints.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Chelyabinsk, Russian Federation
- Chelyabinsk Regional Clinical Oncology Center
-
Moscow, Russian Federation
- Russian Oncological Research Center n.a. N.N. Blokhin
-
Obninsk, Russian Federation
- Medical Radiological Research Center
-
Omsk, Russian Federation
- Omsk Regional Budget Medical Institution
-
-
-
-
Arkansas
-
Fayetteville, Arkansas, United States, 72707
- Highlands Oncology Group
-
-
California
-
San Francisco, California, United States, 94120
- California Pacific Medical Center
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University Melvin and Bren Simon Cancer Center
-
-
New Jersey
-
Newark, New Jersey, United States, 07103
- UMDNJ - New Jersey Medical School
-
-
New York
-
New Hyde Park, New York, United States, 11040
- NSLIJ Health System, Monter Cancer Center
-
New York, New York, United States, 10029
- Mount Sinai School of Medicine
-
Syracuse, New York, United States, 13210
- SUNY Upstate Medical University
-
-
Washington
-
Seattle, Washington, United States, 90108
- Seattle Cancer Care Alliance
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Key Inclusion Criteria:
- Patients with histologically confirmed Stage IV adenocarcinoma of the pancrease previously untreated for metastatic disease
- One or more metastatic tumors measurable on CT scan per RECIST 1.1 criteria
- Life expectancy of at least 3 months
- Signed, written IRB/EC-approved informed consent
- A negative serum pregnancy test, if female
Key Exclusion Criteria:
- Known brain metastasis
- New York Heart Association Class III or IV cardiac disease, myocardial infarction within the past 12 months
- Active, uncontrolled bacterial, viral, or fungal infection requiring systemic therapy
- Known allergy to hyaluronidase
- Women currently pregnant or breast feeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Gemcitabine
Gemcitabine + Placebo
|
1000 mg/m2 given IV one time a week (Cycle 1: 7 weeks on treatment, 1 week off treatment; Cycle 2+: 3 Weeks on treatment, 1 week off treatment)
Other Names:
(Cycle 1: 7 weeks on treatment/1 week off treatment; Cycle 2+: 3 Weeks on treatment/1 week off treatment).
Other Names:
|
Experimental: PEGPH20
PEGPH20+Gemcitabine
|
1000 mg/m2 given IV one time a week (Cycle 1: 7 weeks on treatment, 1 week off treatment; Cycle 2+: 3 Weeks on treatment, 1 week off treatment)
Other Names:
(Cycle 1: 7 weeks on treatment/1 week off treatment; Cycle 2+: 3 Weeks on treatment/1 week off treatment).
Doses start at 1.0 mcg/kg and modified until recommended Phase 2 dose is determined.
Treatment continues until occurrence of significant treatment-related toxicity, progressive disease, or discontinuation criteria are met
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With a Dose-limiting Toxicity (DLT)
Time Frame: first 4 weeks of Cycle 1
|
The safety and tolerability profile of PEGPH20 used in combination with gemcitabine was assessed by measuring the number of participants with a DLT during the dose-escalation phase of the study.
A DLT was defined as any treatment-emergent National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event (CTCAE), Version 4.0, Grade 3 or greater event occurring within the first 4 weeks of treatment that was considered related to PEGPH20.
Any PEGPH20 treatment-related AE that resulted in a drug interruption or reduction might have been considered a DLT at the Investigator's or Sponsor's discretion.
Hypersensitivity/infusion reactions related to PEGPH20 dosing were not considered DLTs.
|
first 4 weeks of Cycle 1
|
Recommended Phase 2 Dose (RP2D)
Time Frame: first 4 weeks of Cycle 1
|
The safety and tolerability profile of PEGPH20 used in combination with gemcitabine was assessed by determining the RP2D, the highest dose level at which no more than 1 of 6 evaluable participants experienced a DLT in the first 4 weeks of treatment (considered a safe dose).
The RP2D was determined based on review of safety and pharmacokinetic (PK) data from participants enrolled during the dose-escalation phase of the study.
|
first 4 weeks of Cycle 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Observed Maximum Plasma Concentration (Cmax) Following Single PEGPH20 Doses
Time Frame: Cycle 1, Week 1, Day 1: First visit: predose; 15 minutes, 1, 2, 4, and 24 hours post-PEGPH20 dosing; all other visits: pre-PEGPH20 dose, 1 to 2 hours post-PEGPH20 dose, and immediately after the dose of gemcitabine (on the days gemcitabine was given)
|
Cmax is defined as the observed maximum plasma concentration after the first dose.
Blood samples were collected for pharmacokinetic assessment.
|
Cycle 1, Week 1, Day 1: First visit: predose; 15 minutes, 1, 2, 4, and 24 hours post-PEGPH20 dosing; all other visits: pre-PEGPH20 dose, 1 to 2 hours post-PEGPH20 dose, and immediately after the dose of gemcitabine (on the days gemcitabine was given)
|
Cmax Following Twice-weekly PEGPH20 Doses for 3 Consecutive Weeks
Time Frame: Cycle 1, Week 4, Day 1: First visit: predose; 15 minutes, 1, 2, 4, and 24 hours post-PEGPH20 dosing; all other visits: pre-PEGPH20 dose, 1 to 2 hours post-PEGPH20 dose, and immediately after the dose of gemcitabine (on the days gemcitabine was given)
|
Cmax is defined as the observed maximum plasma concentration after the first dose.
Blood samples were collected for pharmacokinetic assessment.
The 24-hour sample collected at the first visit was optional.
|
Cycle 1, Week 4, Day 1: First visit: predose; 15 minutes, 1, 2, 4, and 24 hours post-PEGPH20 dosing; all other visits: pre-PEGPH20 dose, 1 to 2 hours post-PEGPH20 dose, and immediately after the dose of gemcitabine (on the days gemcitabine was given)
|
Last Measurable Observed Plasma Concentration (Cmin) Following Single PEGPH20 Doses
Time Frame: Cycle 1, Week 1, Day 1: First visit: predose; 15 minutes, 1, 2, 4, and 24 hours post-PEGPH20 dosing; all other visits: pre-PEGPH20 dose, 1 to 2 hours post-PEGPH20 dose, and immediately after the dose of gemcitabine (on the days gemcitabine was given)
|
Blood samples were collected for pharmacokinetic assessment.
|
Cycle 1, Week 1, Day 1: First visit: predose; 15 minutes, 1, 2, 4, and 24 hours post-PEGPH20 dosing; all other visits: pre-PEGPH20 dose, 1 to 2 hours post-PEGPH20 dose, and immediately after the dose of gemcitabine (on the days gemcitabine was given)
|
Cmin Following Twice-weekly PEGPH20 Doses for 3 Consecutive Weeks
Time Frame: Cycle 1, Week 4, Day 1: First visit: predose; 15 minutes, 1, 2, 4, and 24 hours post-PEGPH20 dosing; all other visits: pre-PEGPH20 dose, 1 to 2 hours post-PEGPH20 dose, and immediately after the dose of gemcitabine (on the days gemcitabine was given)
|
Blood samples were collected for pharmacokinetic assessment.
The 24-hour sample collected at the first visit was optional.
|
Cycle 1, Week 4, Day 1: First visit: predose; 15 minutes, 1, 2, 4, and 24 hours post-PEGPH20 dosing; all other visits: pre-PEGPH20 dose, 1 to 2 hours post-PEGPH20 dose, and immediately after the dose of gemcitabine (on the days gemcitabine was given)
|
Time to Reach Cmax (Tmax) Following Single PEGPH20 Doses
Time Frame: Cycle 1, Week 1, Day 1: First visit: predose; 15 minutes, 1, 2, 4, and 24 hours post-PEGPH20 dosing; all other visits: pre-PEGPH20 dose, 1 to 2 hours post-PEGPH20 dose, and immediately after the dose of gemcitabine (on the days gemcitabine was given)
|
Blood samples were collected for pharmacokinetic assessment.
|
Cycle 1, Week 1, Day 1: First visit: predose; 15 minutes, 1, 2, 4, and 24 hours post-PEGPH20 dosing; all other visits: pre-PEGPH20 dose, 1 to 2 hours post-PEGPH20 dose, and immediately after the dose of gemcitabine (on the days gemcitabine was given)
|
Tmax Following Twice-weekly PEGPH20 Doses for 3 Consecutive Weeks
Time Frame: Cycle 1, Week 4, Day 1: First visit: predose; 15 minutes, 1, 2, 4, and 24 hours post-PEGPH20 dosing; all other visits: pre-PEGPH20 dose, 1 to 2 hours post-PEGPH20 dose, and immediately after the dose of gemcitabine (on the days gemcitabine was given)
|
Blood samples were collected for pharmacokinetic assessment.
The 24-hour sample collected at the first visit was optional.
|
Cycle 1, Week 4, Day 1: First visit: predose; 15 minutes, 1, 2, 4, and 24 hours post-PEGPH20 dosing; all other visits: pre-PEGPH20 dose, 1 to 2 hours post-PEGPH20 dose, and immediately after the dose of gemcitabine (on the days gemcitabine was given)
|
Apparent Half-life (t1/2) Following Single PEGPH20 Doses
Time Frame: Cycle 1, Week 1, Day 1: First visit: predose; 15 minutes, 1, 2, 4, and 24 hours post-PEGPH20 dosing; all other visits: pre-PEGPH20 dose, 1 to 2 hours post-PEGPH20 dose, and immediately after the dose of gemcitabine (on the days gemcitabine was given)
|
The apparent half-life calculated by ln(2)/λ, where λ was the rate constant for the log-linear portion of the terminal phase.
A minimum of 3 values in the postdistribution phase of the plasma concentration-time curve were required for calculation of λ.
Blood samples were collected for pharmacokinetic assessment.
t1/2 is expressed as harmonic mean and pseudo standard deviation.
|
Cycle 1, Week 1, Day 1: First visit: predose; 15 minutes, 1, 2, 4, and 24 hours post-PEGPH20 dosing; all other visits: pre-PEGPH20 dose, 1 to 2 hours post-PEGPH20 dose, and immediately after the dose of gemcitabine (on the days gemcitabine was given)
|
t1/2 Following Twice-weekly PEGPH20 Doses for 3 Consecutive Weeks
Time Frame: Cycle 1, Week 4, Day 1: First visit: predose; 15 minutes, 1, 2, 4, and 24 hours post-PEGPH20 dosing; all other visits: pre-PEGPH20 dose, 1 to 2 hours post-PEGPH20 dose, and immediately after the dose of gemcitabine (on the days gemcitabine was given)
|
The apparent half-life calculated by ln(2)/λ, where λ was the rate constant for the log-linear portion of the terminal phase.
A minimum of 3 values in the postdistribution phase of the plasma concentration-time curve were required for calculation of λ.
Blood samples were collected for pharmacokinetic assessment.
The 24-hour sample collected at the first visit was optional.
t1/2 is expressed as harmonic mean and pseudo standard deviation.
|
Cycle 1, Week 4, Day 1: First visit: predose; 15 minutes, 1, 2, 4, and 24 hours post-PEGPH20 dosing; all other visits: pre-PEGPH20 dose, 1 to 2 hours post-PEGPH20 dose, and immediately after the dose of gemcitabine (on the days gemcitabine was given)
|
Area Under the Plasma Concentration-time Curve From Time 0 to the Time of the Last Measurable Plasma Concentration (AUC0-T) Following Single PEGPH20 Doses
Time Frame: Cycle 1, Week 1, Day 1: First visit: predose; 15 minutes, 1, 2, 4, and 24 hours post-PEGPH20 dosing; all other visits: pre-PEGPH20 dose, 1 to 2 hours post-PEGPH20 dose, and immediately after the dose of gemcitabine (on the days gemcitabine was given)
|
Blood samples were collected for pharmacokinetic assessment.
AUC0-T was calculated by the linear trapezoidal rule.
|
Cycle 1, Week 1, Day 1: First visit: predose; 15 minutes, 1, 2, 4, and 24 hours post-PEGPH20 dosing; all other visits: pre-PEGPH20 dose, 1 to 2 hours post-PEGPH20 dose, and immediately after the dose of gemcitabine (on the days gemcitabine was given)
|
AUC0-T Following Twice-weekly PEGPH20 Doses for 3 Consecutive Weeks
Time Frame: Cycle 1, Week 4, Day 1: First visit: predose; 15 minutes, 1, 2, 4, and 24 hours post-PEGPH20 dosing; all other visits: pre-PEGPH20 dose, 1 to 2 hours post-PEGPH20 dose, and immediately after the dose of gemcitabine (on the days gemcitabine was given)
|
Blood samples were collected for pharmacokinetic assessment.
The 24-hour sample collected at the first visit was optional.
AUC0-T was calculated by the linear trapezoidal rule.
|
Cycle 1, Week 4, Day 1: First visit: predose; 15 minutes, 1, 2, 4, and 24 hours post-PEGPH20 dosing; all other visits: pre-PEGPH20 dose, 1 to 2 hours post-PEGPH20 dose, and immediately after the dose of gemcitabine (on the days gemcitabine was given)
|
Plasma Hyaluronan (HA) Concentration at Baseline and After PEGPH20 Administration
Time Frame: Baseline; post-Baseline (average treatment duration of 94.6 days)
|
The pharmacodynamic activity of PEGPH20 was evaluated by measuring plasma concentrations of HA after PEGPH20 dosing.
Peak HA concentrations are the highest concentrations measured after a single dose of PEGPH20.
HA samples were collected in Cycle 1 at the following time points: 1) Week 1/Day 1 (first visit) and Week 4 (first visit): predose and 15 minutes, 1, 2, 4, and 24 hours post-PEGPH20 dosing (24-hour sample optional for Week 4); 2) all other visits in Cycle 1: pre-PEGPH20 dose, 1 to 2 hours post-PEGPH20 dose, and immediately after the dose of gemcitabine (on the days gemcitabine was given).
HA samples were collected in Cycles 2+ at the following time points: Week 3 of each cycle pre-PEGPH20 dose and 1 to 2 hours post-PEGPH20 dose.
|
Baseline; post-Baseline (average treatment duration of 94.6 days)
|
H-scores, as an Assessment of HA Staining Changes in Tumor Biopsies
Time Frame: Screening; Cycle 1 Week 7
|
An H-score approach methodology was developed and used to analyze staining in the tumor pericellular regions and the stroma separately.
The H-score calculation was the sum of the products of the percentage of positive staining areas and the staining intensity (0, 1, 2 or 3), and ranged from 0 to 300.
For example: [90% * 1 (weak)] + [10% * 2 (moderate)] + [0% * 3 (strong)] = 110.
A score of 0 represents the absence of expression, and an H-score of 300 represents maximum expression.
A larger decrease in H-score correlated with a greater target engagement of PEGPH20.
As HA is a secreted protein, the scoring was performed in the immediate areas surrounding tumor (pericellular areas) as well as in stroma.
|
Screening; Cycle 1 Week 7
|
Percent Change in in the Maximum Standardized Uptake Value (SUVmax), as an Assessment of Total Lesion Metabolic Activity
Time Frame: Baseline; up to 32 weeks for each individual participant (end of Cycle 7)
|
PEGPH20's effect on the metabolic activities of the tumor was assessed as the percent change in SUVmax (a measure of total lesion metabolic activity) using fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT).
Assessment was done for the entire cohort of participants, not per treatment group.
|
Baseline; up to 32 weeks for each individual participant (end of Cycle 7)
|
Mean Volume Transfer Constant (Ktrans) for Scans Across Tissue Sites
Time Frame: Baseline; 24 hours hours; end of Cycle 1 (Week 7)
|
Dynamic control enhanced-magnetic resonance imaging (DCE-MRI) provides a measure of the exchange of small-molecule contrast agents between the intracellular and extracellular spaces.
Using a 2-compartment pharmacokinetic model, an estimate of tissue (tumor) perfusion can be obtained by determining the exchange rate constant (Ktrans) of contrast exchange.
Ktrans is defined as the volume transfer constant between extravascular/extracellular space to plasma space and is a measure of blood flow, vascular permeability, or both.
Mean Ktrans values across scan sites are reported per participant.
DCE-MRI was performed before the first dosing visit (Week 1/Day 1), 24 hours after the first dose of PEGPH20 in Cycle 1, and 24 hours after the last dose of PEGPH20 in Cycle 1 (Week 7).
Assessment was done for the entire cohort of participants, not per treatment group.
|
Baseline; 24 hours hours; end of Cycle 1 (Week 7)
|
Mean Extravascular-Extracellular Volume Fraction (Ve) for Scans Across Tissue Sites
Time Frame: Baseline; 24 hours hours; end of Cycle 1 (Week 7)
|
DCE-MRI provides a measure of the exchange of small-molecule contrast agents between the intracellular and extracellular spaces.
Ve is defined as the extravascular-extracellular volume fraction and is a measure of extracellular, extravascular space.
Mean Ve values across scan sites are reported per participant.
DCE-MRI was performed before the first dosing visit (Week 1/Day 1), 24 hours after the first dose of PEGPH20 in Cycle 1, and 24 hours after the last dose of PEGPH20 in Cycle 1 (Week 7).
Assessment was done for the entire cohort of participants, not per treatment group.
|
Baseline; 24 hours hours; end of Cycle 1 (Week 7)
|
Number of Participants With the Indicated Best Response, Per Response Evaluation Criteria in Solid Tumors (RECIST), Version 1.1
Time Frame: up to approximately 2 years 4 months
|
Target lesions (TLs), complete response (CR): Disappearance of all TLs.
Partial response (PR): >=30% decrease in the sum of diameters of TLs, referencing baseline sums.
Progressive disease (PD): >= 20% increase in the sum of diameters of TLs, referencing the smallest sum (including baseline sum).
In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of >=5 mm.
(The appearance of >=1 new lesions is considered progression.)
Stable disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient to qualify for PD, referencing the smallest sum diameters.
For nontarget lesions (NTLs), CR: Disappearance of all NTLs and normalization of tumor marker level.
All lymph nodes must be nonpathological in size (short axis <10 mm).
Incomplete response/SD: Persistence of >=1 NTLs and/or maintenance of tumor marker level above normal limits.
PD: Unequivocal progression of existing NTLs.
(The appearance of >=1 new lesions is considered progression.)
|
up to approximately 2 years 4 months
|
Objective Response Rate
Time Frame: up to approximately 2 years 4 months
|
Objective Response Rate is defined as the number of participants with a complete response plus the number of participants with a partial response, per RECIST, Version 1.1.
For TLs, CR: Disappearance of all TLs.
PR: >=30% decrease in the sum of diameters of TLs, referencing baseline sums.
For NTLs, CR: Disappearance of all NTLs and normalization of tumor marker level.
All lymph nodes must be nonpathological in size (short axis <10 mm).
Incomplete response/SD: Persistence of >=1 NTLs and/or maintenance of tumor marker level above normal limits.
|
up to approximately 2 years 4 months
|
Disease Control Rate
Time Frame: up to approximately 2 years 4 months
|
Disease Control Rate is defined as the sum of the number of participants with a complete response, the number of participants with a partial response, and the number of participants with stable disease per RECIST, Version 1.1.
For TLs, CR: Disappearance of all TLs.
PR: >=30% decrease in the sum of diameters of TLs, referencing baseline sums.
SD: Neither sufficient shrinkage to qualify for PR nor sufficient to qualify for PD, referencing the smallest sum diameters.
For NTLs, CR: Disappearance of all NTLs and normalization of tumor marker level.
All lymph nodes must be nonpathological in size (short axis <10 mm).
Incomplete response/SD: Persistence of >=1 NTLs and/or maintenance of tumor marker level above normal limits.
|
up to approximately 2 years 4 months
|
Progression-free Survival (PFS)
Time Frame: from the first dose of PEGH20 until objective tumor progression or death (up to approximately 2 years 4 months)
|
PFS duration was defined as the time from the first dose of PEGPH20 until objective tumor progression or death.
Per RECIST, Version 1.1, for the evaluation of target lesions, progressive disease is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).
In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeters.
Note: the appearance of 1 or more new lesions is also considered progression.
For the evaluation of nontarget lesions, progressive disease is defined as the unequivocal progression of existing nontarget lesions.
Note: The appearance of 1 or more new lesions is also considered progression.
|
from the first dose of PEGH20 until objective tumor progression or death (up to approximately 2 years 4 months)
|
Overall Survival
Time Frame: from the time of the first dose of PEGPH20 until death (up to approximately 2 years 4 months)
|
Overall survival was defined as the time from the time of the first dose of PEGPH20 until death.
|
from the time of the first dose of PEGPH20 until death (up to approximately 2 years 4 months)
|
Change From Baseline in Carbohydrate Antigen 19-9 or Sialylated Lewis(a) Antigen (CA19-9)
Time Frame: up to the end of Cycle 10 (up to Week 44)
|
CA19-9 is a tumor marker.
Blood samples (plasma) were collected for CA19-9 evaluations.
|
up to the end of Cycle 10 (up to Week 44)
|
Change From Baseline in CA19-9 in Participants With a Baseline Value >=59 U/ml
Time Frame: up to the end of Cycle 10 (up to Week 44)
|
CA19-9 is a tumor marker.
Blood samples (plasma) were collected for CA19-9 evaluations.
|
up to the end of Cycle 10 (up to Week 44)
|
Change From Baseline in CA19-9 in Participants Classified as Responders and Non-responders
Time Frame: up to the end of Cycle 10 (up to Week 44)
|
CA19-9 is a tumor marker.
Blood samples (plasma) were collected for CA19-9 evaluations.
Responders are defined as participants who had a complete response or partial response, and non-responders are defined as participants who had stable disease, progressive disease, or an unknown tumor response, per RECIST, Version 1.1.
|
up to the end of Cycle 10 (up to Week 44)
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Joy H Zhu, MD, PhD, Halozyme Therapeutics
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Pancreatic Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Gemcitabine
Other Study ID Numbers
- Halo-109-201
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stage IV Pancreatic Cancer
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CelgeneWithdrawnPancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Panbela Therapeutics, Inc.CompletedPancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Stage IV Pancreatic CancerUnited States, Australia
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedRecurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer | Stage IV Gastric Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Recurrent Gastric Cancer | Stage III Colon Cancer | Stage III Gastric Cancer | Stage III Rectal...United States
-
University of ChicagoNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Gastric Adenocarcinoma | Metastatic Pancreatic Adenocarcinoma | Malignant Gastrointestinal Neoplasm | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Gallbladder Carcinoma | Stage IV Gallbladder Cancer | Stage IV Gastric Cancer | Stage IIIA Gallbladder Cancer | Stage... and other conditionsUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI); National Institute of Nursing Research (NINR)CompletedStage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic CancerUnited States
-
Jerome Canady, M.D.Active, not recruitingStage IV Lung Cancer | Stage IV Bladder Cancer | Stage IV Pancreatic Cancer | Recurrent Malignant Solid Neoplasm | Stage IV Breast Cancer | Stage IV Renal Cell Cancer | Stage IV Prostate Cancer | Stage IV Colon Cancer | Stage IV Rectal Cancer | Stage IV Gastric Cancer | Stage IV Non-small Cell Lung Cancer | Stage... and other conditionsUnited States
-
Emory UniversityIpsen; Taiho Oncology, Inc.RecruitingGastric Adenocarcinoma | Unresectable Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Colorectal Adenocarcinoma | Stage IV Gastric Cancer | Stage IV Colorectal Cancer | Stage IVA Colorectal Cancer | Stage IVB Colorectal Cancer | Stage... and other conditionsUnited States
-
University of UtahNovartis PharmaceuticalsRecruitingMetastatic Pancreatic Carcinoma | Unresectable Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic CancerUnited States
-
Seoul National University HospitalNational Cancer Center, Korea; Chonbuk National University Hospital; Asan Medical... and other collaboratorsCompletedStage IV Lung Cancer | Stage IV Pancreatic Cancer | Stage IV Breast Cancer | Pediatric Brain Tumor | Stage IV Colon Cancer | Stage IV Gastric Cancer | Stage IV Liver Cancer | Malignant Hematologic Neoplasm | Pediatric Solid Tumor | Pediatric Lymphoma | Biliary Cancer Metastatic | Pediatric LeukemiaKorea, Republic of
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityRecruitingPancreatic Adenocarcinoma | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Stage 0 Pancreatic Cancer AJCC v8 | Stage I Pancreatic Cancer AJCC v8United States
Clinical Trials on Gemcitabine
-
AstraZenecaRecruitingBiliary Tract CancerFrance, Spain, Italy, Korea, Republic of, Japan, Germany, United States, Singapore
-
Sierra Oncology LLC - a GSK companyCompletedAdvanced Solid TumorsSpain, United Kingdom
-
University of Erlangen-Nürnberg Medical SchoolCompleted
-
Shenzhen University General HospitalNot yet recruiting
-
3D Medicines (Sichuan) Co., Ltd.Not yet recruitingBiliary Tract Neoplasms
-
Kansai Hepatobiliary Oncology GroupCompleted
-
Fifth Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
3D Medicines (Sichuan) Co., Ltd.RecruitingBiliary Tract NeoplasmsChina
-
Yung NAQueen Mary Hospital, Hong Kong; Pamela Youde Nethersole Eastern HospitalRecruitingMuscle-Invasive Bladder Carcinoma | Muscle Invasive Bladder Urothelial CarcinomaHong Kong
-
Air Force Military Medical University, ChinaRecruiting